Original Research Article DOI: 10.18231/2394-2797.2017.0018 International Journal of Pharmaceutical Chemistry and Analysis, 4(3):79-82 79 Simultaneous Determination of Dexibuprofen and Tramadol HCl by HPTLC Method Prachi Pimple Assistant Professor, Dept. of Pharmaceutics, Viva Institute of Pharmacy, Thane, Maharashtra Email: prachipatil1984@gmail.com Abstract Introduction: Aim of the study is to develop simple, specific, accurate HPTLC method for simultaneous determination of the Dexibuprofen and Tramadol HCl in pharmaceutical dosage form. Materials and Method: Stationary phase was precoated silica gel 60 F254. The Mobile Phase used was mixture of Chloroform: toluene: ethanol: glacial acetic acid (8:4:1:0.5 v/v/v/v). The detection of the spots was carried out at 264nm and 271nm for Dexibuprofen and Tramadol HCl respectively. Result: The method was validated in terms of linearity, accuracy, precision and specificity. The Limit of detection for Dexibuprofen and Tramadol HCl was found to be 1μg and 0. 2 μg respectively. The Limit of quantification for Dexibuprofen and Tramadol HCl was found to be 1.6μg and 0.4μg respectively. Conclusion: The method is free from the interferences due to excipients present in the formulation and can be successfully used for determine drug in pharmaceutical dosage form. Keywords: Dexibuprofen, Tramadol HCl, HPTLC method, Simultaneous determination Introduction Dexibuprofen is chemically (S)-Alpha-Methyl-4- (2-Methyl Propyl) Benzene Acetic Acid. Dexibuprofen is a pharmacologically active enantiomer of racemic ibuprofen. Racemic ibuprofen is a non-steroidal substance with anti-inflammatory and analgesic effects. Its mechanism of action is due to inhibition of prostaglandin synthesis. (1) Tramadol Hclischemicallyrac-(1R,2R)-2-(dimethylaminomethyl)- 1-(3-methoxyphenyl)-cyclohexanolit work through modulation of the GABAergic, noradrenergic and serotonergic systems, in addition to its mild agonism of the ȝ-opioid receptor. (2) Fig. 1: Dexibuprofen Fig. 2: Tramadol It is reported that the addition of Tramadol HCl 37.5mg tablets (four times daily) for 5 days to existing NSAID therapy provides effective pain relief in patients with osteoarthritis flare pain. Liquid filled capsules containing 475mg Dexibuprofen and Tramadol HCl combination if taken twice in a day are effective novel dosage forms for osteoarthritis. (2) The objective of the work is to develop the new HPTLC method for simultaneous of Dexibuprofen and Tramadol HCl in pharmaceutical dosage form. Materials and Method Dexibuprofen and Tramadol HCl pure powder sample were gifted by Glochem Industries Limited and Oranosys Pharma Respectively. The HPTLC system (Linomate IV Applicator and Camag scanner IV) was used for the development of the method. Instrumentation Camag Linomat IV as sample applicator, Camag TLC scanner II, Camag Twin tough chamber were used. HPTLC pre-coated plates with silica gel 60F (20x10 cm) Merck 5642 were used. Development of mobile phase Number of polar and non-polar solvent combinations were attempted to develop the mobile phase. Mobile phase containing chloroform: toluene: ethanol: glacial acetic acid (8:4:1:0.5 v/v/v/v) gave best resolution without tailing so it was finalized as mobile phase for method development for simultaneous determination of Dexibuprofen and Tramadol HCl.